Steven Yu

Steven Yu has extensive work experience spanning over several years. Steven currently holds the role of SVP at Transcenta since March 2021. Prior to that, they worked as VP at ChemPartner from August 2020 to March 2021, and as VP at LH Group from September 2019 to August 2020. Steven also served as Associate Director/Global DMPK lead at Takeda from January 2019 to August 2019, and as Associate Director at Shire Pharmaceuticals from January 2018 to January 2019.

Before joining Shire Pharmaceuticals, Steven held the position of Principal Scientist at Boehringer Ingelheim from an unspecified start date to January 2018. Steven also worked at Amgen as a Senior Scientist/Manager from an unspecified start date to 2014, and at Invitrogen as a Scientist from an unspecified start date to 2006.

Steven started their career as a Medical Representative at Pfizer in the China branch from an unspecified start date to 1995. Steven also worked as a Doctoral Fellow at Loma Linda University, Center for Molecular Biology & Gene Therapy from an unspecified start date to 2004, where they developed oral vaccines for Type I diabetes and immunoassays for infectious diseases.

Steven Yu earned a Bachelor of Science (BS) degree in Microbiology from Sichuan University between the years 1985 and 1989. Steven then pursued further education at Loma Linda University from 1995 to 2001, completing a PhD in Biochemistry. Lastly, Steven attended Pepperdine Graziadio Business School from 2006 to 2010, earning an MBA degree with a focus on International Business.